Adalta Ltd. · ASX:1AD
Adalta — BIO International Convention 2022
25 slides from Adalta's conference presentation, Jun 1, 2022
Slide 1: AdAlta to present at BIO International Convention
1 June 2022 ASX Announcement AdAlta to present at BIO International Convention MELBOURNE Australia, 1 June 2022: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to advise that CEO and Managing Director, Dr
Slide 2: Notes to Editors: About AdAlta
Notes to Editors About AdAlta AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody p
Slide 3: Developing high value drugs for challenging diseases
Developing high value drugs for challenging diseases Tim Oldham PhD, CEO and Managing Director BIO2022
Slide 4: Disclaimer
COMPANY OVERVEIW – MAY 2022 2 Disclaimer Investment in AdAlta is subject to This presentation may contain forward- There is no guarantee that the investment risk, including possible loss looking statements regarding the Company’s research and development of income and capital invested. AdAlta potent
Slide 5: AdAlta at a glance
COMPANY OVERVEIW – MAY 2022 3 AdAlta at a glance Building out pipeline Targeting 10 programs by end 2023 Immuno-oncology: two co-development collaborations 1. i-CAR-T with Carina Biotech: US$20b market by 2028 2. GZMB i-PET imaging agent with GE Healthcare: US$6.4b market Fibrosis/inflammation: whol
Slide 6: Four human health needs AdAlta is addressing today
COMPANY OVERVEIW – MAY 2022 4 Four human health needs AdAlta is addressing today Antibodies cannot do everything! AdAlta’s i-bodies are a differentiated drug discovery platform for difficult diseases Idiopathic Pulmonary Fibrosis: degenerative, fatal AdAlta’s AD-214 could meet a desperate need for n
Slide 7: Platform: i-bodies
Platform: i-bodies
Slide 8: i-bodies: sdAB-like molecules with engineered binding loops
COMPANY OVERVEIW – MAY 2022 6 i-bodies: sdAB-like molecules with engineered binding loops conferring unique binding properties i-bodies are combination of i-body library contains 1010 1 a human protein with unique long loop 2 unique i-bodies. Each unique i-body has binding sites that mimic the struc
Slide 9: i-bodies allow for high affinity, high specificity binding to intractable targets
COMPANY OVERVEIW – MAY 2022 7 i-bodies allow for high affinity, high specificity binding to targets that are intractable for traditional antibodies Small Antibodies i-bodies Flexible, modular formats Molecules CAR cell therapy ADC/ radiotherapeutic Bi-specific Fc-fusion i-bodies have high i-bodies a
Slide 10: Lead program: AD-214
Lead program: AD-214 8
Slide 11: About | Idiopathic Pulmonary Fibrosis (IPF)
COMPANY OVERVEIW – MAY 2022 9 About | Idiopathic Pulmonary Fibrosis (IPF) Scaring and stiffening of the lungs progressively and irreversibly reduces lung function >300,000 people living with IPF; 40,000 people die from IPF every year Only 3.8 years median survival after diagnosis Two current therapi
Slide 12: AD-214 | Completed Phase I, preparing superior inhalation format for Phase II
COMPANY OVERVEIW – MAY 2022 10 AD-214 | Completed Phase I, preparing superior inhalation format for Phase II AD-214 is a first in class anti-fibrotic Direct lung delivery (inhalation) potentially a superior format • i-body-Fc fusion targeting CXCR4 for IPF3 • Pre-clinical efficacy in lung, kidney, e
Slide 13: Inhaled AD-214 | Milestones and opportunities in 2022
COMPANY OVERVEIW – MAY 2022 11 Inhaled AD-214 | Milestones and opportunities in 2022 June 2022 Through mid CY 2022 September 2022 quarter December 2022 quarter quarter • Antifibrotic effects in cultured human lung • Preparation for inhalation tissue • Efficacy in bleomycin toxicology studies • Antif
Slide 14: AD-214 | Valuable IPF partnering options as early as Phase I
COMPANY OVERVEIW – MAY 2022 12 AD-214 | Valuable IPF partnering options as early as Phase I Date Licensee Licensor Transaction Terms Clinical Phase Nov-21 US$254m Upfront 2 (Ready) Nov-21 €320m Milestones 2 (Ready) US$152m Upfront Sep-21 2 (Ready) +US$602m Milestones US$390m Upfront Nov-19 2 +US$1b
Slide 15: AD-214 | Multiple indication extension options in other forms of fibrosis
COMPANY OVERVEIW – MAY 2022 13 AD-214 | Multiple indication extension options in other forms of fibrosis • Preclinical tissue and animal models show that AD-214 may improve fibrosis across a range of fibrotic diseases and cancer Lung Eye Cancer IPF/ILD Wet-AMD 23 different cancers, I/O >US$3b >US$15
Slide 16: Co-developed immuno-oncology assets
Co-developed immuno-oncology assets 14
Slide 17: About | CAR-T therapies
COMPANY OVERVEIW – MAY 2022 15 About | CAR-T therapies CAR-T therapies are providing new hope for patients with cancer who have failed all other options Therapy involves removing immune cells from blood and re-engineering them so they “see” cancer as a pathogen Already 6 FDA-approved CAR-T therapies
Slide 18: i-bodies enable optimized CAR constructs (i-CARs)
COMPANY OVERVEIW – MAY 2022 16 i-bodies enable optimized CAR constructs (i-CARs) Feature Benefit Superior i-CAR products • Increased CAR gene cassette/vector capacity, • CARs against novel tumor antigens Small size efficient multi-functional CAR cell creation • Dual and bi-specific CARs for enhanced
Slide 19: i-CAR-T assets | Carina co-development collaboration
COMPANY OVERVEIW – MAY 2022 17 i-CAR-T assets | Carina co-development collaboration AdAlta and Carina are combining i-bodies and a world class CAR-T platform to create iCAR-Ts that could offer improved precision, performance and persistence Further expands AdAlta’s pipeline in an attractive deal spa
Slide 20: About | Immuno-oncology (I/O) PET imaging
COMPANY OVERVEIW – MAY 2022 18 About | Immuno-oncology (I/O) PET imaging Immuno-oncology (I/O) drug market is worth US$95 billion1 … … but only 20-40% of patients respond2 to therapy Granzyme B (GZMB) is produced by immune cells to kill cancer: potential biomarker of I/O drug activation of the immun
Slide 21: GZMB i-PET imaging asset | GE Healthcare co-development collaboration
COMPANY OVERVEIW – MAY 2022 19 GZMB i-PET imaging asset | GE Healthcare co-development collaboration AdAlta and GE are co-developing a GZMB i-body PET imaging (iPET) asset to evaluate the effectiveness of immuno-oncology drugs Revenue generative pipeline asset • AdAlta earns research fees, developme
Slide 22: I/O assets | Milestones and opportunities in 2022
COMPANY OVERVEIW – MAY 2022 20 I/O assets | Milestones and opportunities in 2022 Through mid CY Through mid CY September 2022 December 2022 2022 2022 quarter quarter iCAR-T Target A • Initial in vitro • in vitro cancer • GZMB iPET cell killing cancer cell killing imaging agent • iCAR-T targets B scr
Slide 23: Corporate snapshot
COMPANY OVERVEIW – MAY 2022 21 Corporate snapshot Key financial details (31 March 2022) Share price performance (last 12 months) ASX code 1AD 0.20 4.0 0.18 3.5 Market capitalisation A$22.94m 0.16 Share price (12 month closing range) A$0.073 ($0.071 - 0.183) 3.0 0.14 12 month return (52)% Share price
Slide 24: Investment proposition
COMPANY OVERVEIW – MAY 2022 22 Investment proposition Fibrosis/inflammation Immuno-oncology Lead asset advancing to Phase II 2 x co-development collaborations to i-body platform to create value >$3b market potential in first indication1 leverage platform ü GE Healthcare: $6b PET market2 Discovery in
Slide 25: Contact: Tim Oldham, CEO and Managing Director
Contact: Tim Oldham, CEO and Managing Director enquiries@adalta.com.au www.adalta.com.au